Stereotaxis targets $40M revenue milestoneMedical device manufacturer Stereotaxis announced ambitious 2026 guidance during its Q4 2025 earnings call, projecting over $40 million in annual revenue as the company accelerates manufacturing operations and launches innovative products. The NYSE-listed company is banking on strong momentum from its GenesisX platform and MAGiC catheter systems to drive growth. Management highlighted expanding recurring revenue streams as a key driver of profitability improvement. The manufacturing ramp represents a critical inflection point for the company as it scales production to meet growing market demand. Investors are watching closely to see if Stereotaxis can execute on these targets while managing operational costs effectively during this growth phase.
Post from MarketNews_en
Log in to interact with content.